Diabetes Drug Class May Hold Promise for Gout Prevention |
Journal Updates
eMediNexus Coverage from: 
Diabetes Drug Class May Hold Promise for Gout Prevention
eMediNexus,  14 January 2020
remove_red_eye 492 Views
#Diabetes and Endocrinology #Internal Medicine #Pharmacist #Rheumatology

1 Read Comments                

Sodium-glucose cotransporter-2 (SGLT2) inhibitors may reduce the risk for gout among adults with type 2 diabetes, new research suggests.

The study, involving more than 200,000 individuals from a US commercial insurance database, was published online January 13 in Annals of Internal Medicine. In this new study, there was a nearly 40% relative risk reduction in gout among adults prescribed SGLT2 inhibitors compared with those prescribed glucagon-like peptide-1 (GLP-1) receptor agonists, which do not decrease uric acid levels. The absolute risk reduction was about three fewer adults with gout per 1000 person-years.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now